

Matthew Mossanen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/212326/publications.pdf>

Version: 2024-02-01

92
papers

1,264
citations

430874

18
h-index

414414

32
g-index

93
all docs

93
docs citations

93
times ranked

1821
citing authors

#	ARTICLE	IF	CITATIONS
1	The burden of bladder cancer care. <i>Current Opinion in Urology</i> , 2014, 24, 487-491.	1.8	138
2	Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 439-439.	1.6	101
3	Individual, interpersonal, and organisational factors of healthcare conflict: A scoping review. <i>Journal of Interprofessional Care</i> , 2017, 31, 282-290.	1.7	78
4	Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. <i>European Urology</i> , 2018, 73, 374-382.	1.9	62
5	Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?. <i>Cancer</i> , 2019, 125, 1449-1458.	4.1	56
6	Use and Outcomes of Extended Antibiotic Prophylaxis in Urological Cancer Surgery. <i>Journal of Urology</i> , 2014, 192, 425-429.	0.4	49
7	Overuse of Antimicrobial Prophylaxis in Community Practice Urology. <i>Journal of Urology</i> , 2015, 193, 543-547.	0.4	44
8	Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. <i>World Journal of Urology</i> , 2019, 37, 2059-2065.	2.2	40
9	Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 23-31.e3.	1.9	40
10	Prophylactic Antibiotics and Postoperative Complications of Radical Cystectomy: A Population Based Analysis in the United States. <i>Journal of Urology</i> , 2017, 198, 297-304.	0.4	35
11	Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer. <i>Cancer</i> , 2019, 125, 3164-3171.	4.1	35
12	Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. <i>European Urology Focus</i> , 2021, 7, 124-131.	3.1	31
13	Associations of specific postoperative complications with costs after radical cystectomy. <i>BJU International</i> , 2018, 121, 428-436.	2.5	30
14	The Epidemiology of Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 445-455.	2.2	28
15	Identification of underserved areas for urologic cancer care. <i>Cancer</i> , 2014, 120, 1565-1571.	4.1	27
16	A contemporary population-based analysis of the incidence, cost, and outcomes of postoperative delirium following major urologic cancer surgeries. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 341.e15-341.e22.	1.6	25
17	Association of Race With Cancer-Related Financial Toxicity. <i>JCO Oncology Practice</i> , 2022, 18, e271-e283.	2.9	23
18	Surgical pathology and the patient: a systematic review evaluating the primary audience of pathology reports. <i>Human Pathology</i> , 2014, 45, 2192-2201.	2.0	22

#	ARTICLE	IF	CITATIONS
19	Patient-centered risk stratification of disposition outcomes following radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 235.e17-235.e23.	1.6	22
20	Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy. <i>European Urology Oncology</i> , 2018, 1, 143-148.	5.4	19
21	The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65 years. <i>Cancer</i> , 2020, 126, 496-505.	4.1	19
22	Readability of urologic pathology reports: The need for patient-centered approaches. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1091-1094.	1.6	18
23	Current Staging Strategies for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2018, 45, 143-154.	1.8	17
24	Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. <i>BJU International</i> , 2019, 124, 40-46.	2.5	17
25	Addressing Financial Toxicity: The Role of the Urologist. <i>Journal of Urology</i> , 2018, 200, 43-45.	0.4	14
26	Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ of the Bladder. <i>Journal of Urology</i> , 2021, 205, 1326-1335.	0.4	14
27	Risk factors and reasons for reoperation after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 269-277.	1.6	13
28	Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis. <i>World Journal of Urology</i> , 2020, 38, 2227-2236.	2.2	12
29	Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: Preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2. <i>Journal of Clinical Oncology</i> , 2020, 38, 507-507.	1.6	12
30	Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. <i>European Urology</i> , 2022, 81, 466-473.	1.9	12
31	Treating Patients With Bladder Cancer: Is There an Ethical Obligation to Include Smoking Cessation Counseling?. <i>Journal of Clinical Oncology</i> , 2018, 36, 3189-3191.	1.6	11
32	The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 500.e11-500.e19.	1.6	10
33	The impact of smoking on radical cystectomy complications increases in elderly patients. <i>Cancer</i> , 2021, 127, 1387-1394.	4.1	10
34	Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. <i>BJU International</i> , 2021, 128, 607-614.	2.5	10
35	Patient driven care in the management of prostate cancer: analysis of the United States military healthcare system. <i>BMC Urology</i> , 2017, 17, 56.	1.4	9
36	Inferring bladder cancer research prioritization from patient-generated online content. <i>World Journal of Urology</i> , 2019, 37, 1145-1150.	2.2	9

#	ARTICLE	IF	CITATIONS
37	The development and comparative effectiveness of a patient-centered prostate biopsy report: a prospective, randomized study. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 144-150.	3.9	9
38	Contemporary Treatment Patterns for Non-muscle-invasive Bladder Cancer: Has the Use of Radical Cystectomy Changed in the BCG Shortage Era?. <i>Urology</i> , 2021, 147, 199-204.	1.0	9
39	Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e651-e659.	1.9	7
40	Comparison of comorbidity indices for prediction of morbidity and mortality after major surgical procedures. <i>American Journal of Surgery</i> , 2021, 222, 998-1004.	1.8	7
41	Defining Factors Associated with High-quality Surgery Following Radical Cystectomy: Analysis of the British Association of Urological Surgeons Cystectomy Audit. <i>European Urology Open Science</i> , 2021, 33, 1-10.	0.4	7
42	Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 528-528.	1.6	7
43	Exploring exposure to Agent Orange and increased mortality due to bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 627-632.	1.6	6
44	Approach to the Patient with High-Risk Prostate Cancer. <i>Urologic Clinics of North America</i> , 2017, 44, 635-645.	1.8	6
45	Cost and cost-effectiveness studies in urologic oncology using large administrative databases. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 213-219.	1.6	6
46	Does overlapping surgery result in worse surgical outcomes? A systematic review and meta-analysis. <i>American Journal of Surgery</i> , 2019, 218, 181-191.	1.8	6
47	Alvimopan Is Associated With a Reduction in Length of Stay and Hospital Costs for Patients Undergoing Radical Cystectomy. <i>Urology</i> , 2020, 140, 115-121.	1.0	6
48	Patient factors predict complications after partial nephrectomy: validation and calibration of the Preoperative Risk Evaluation for Partial Nephrectomy (PREP) score. <i>BJU International</i> , 2021, 127, 369-374.	2.5	6
49	Therapy for Muscle-Invasive Urothelial Carcinoma: Controversies and Dilemmas. <i>Journal of Clinical Oncology</i> , 2022, 40, 1275-1280.	1.6	6
50	Quality Improvement Efforts in Radical Cystectomy: From Prehab to Rehab. <i>European Urology</i> , 2018, 73, 372-373.	1.9	5
51	Trends in Adherence to Thromboprophylaxis Guideline in Patients Undergoing Radical Cystectomy. <i>Urology</i> , 2020, 135, 44-49.	1.0	5
52	The cost of obesity in radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 932.e9-932.e14.	1.6	5
53	Genomic landscape of variant urinary tumor histologies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 467-467.	1.6	4
54	Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 436.e1-436.e10.	1.6	4

#	ARTICLE	IF	CITATIONS
55	Robotic-assisted radical cystectomy is associated with lower perioperative mortality in octogenarians. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 163.e19-163.e23.	1.6	4
56	Beyond bladder cancer surveillance: building a survivorship clinic. <i>BJU International</i> , 2020, 125, 2-3.	2.5	3
57	Delay in surgery for cT1b-2 kidney cancer beyond 90 days is associated with poorer survival: implications for prioritization during the COVID-19 pandemic. <i>Minerva Urology and Nephrology</i> , 2021, 73, 404-406.	2.5	3
58	Clinical characterization of radiation-associated muscle-invasive bladder cancer. <i>Urology</i> , 2021, 154, 208-214.	1.0	3
59	Cyclophosphamide-associated bladder cancers and considerations for survivorship care: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 678-685.	1.6	3
60	Shared decision making for prostate cancer screening: Reality or farce?. <i>Journal of Clinical Oncology</i> , 2018, 36, 107-107.	1.6	3
61	Well-being beyond the bladder. How do we improve the overall health of patients with bladder cancer?. <i>BJU International</i> , 2018, 121, 489-491.	2.5	2
62	Exploring Patterns of Mitomycin C Use in Community Practice Urology. <i>Urology Practice</i> , 2018, 5, 7-14.	0.5	2
63	The impact of readmission hospital on failure-to-rescue rates following major urologic cancer surgery. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 156.e1-156.e7.	1.6	2
64	Charge-to-Cost Ratio Varies among Common Urological Surgery Procedures. <i>Urology Practice</i> , 2018, 5, 349-350.	0.5	2
65	Hospital Charges for Urologic Surgery Episodes of Care Are Rising Despite Declining Costs. <i>Mayo Clinic Proceedings</i> , 2019, 94, 995-1002.	3.0	2
66	Temporal trends in the incidence of distant-stage bladder cancer among young individuals. <i>International Journal of Urology</i> , 2021, 28, 704-705.	1.0	2
67	Impact of late Medicaid expansion on prostate cancer screening.. <i>Journal of Clinical Oncology</i> , 2018, 36, 141-141.	1.6	2
68	Association between Operative Time and Short-Term Radical Cystectomy Complications. <i>Urologia Internationalis</i> , 2023, 107, 273-279.	1.3	2
69	Delayed blood transfusion is associated with mortality following radical cystectomy. <i>Scandinavian Journal of Urology</i> , 2020, 54, 290-296.	1.0	1
70	Physician and facility drivers of spending variation in locoregional prostate cancer. <i>Cancer</i> , 2020, 126, 1622-1631.	4.1	1
71	Best practices for assessing and reporting tobacco use in urology oncology practice and research. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 446-451.	1.6	1
72	Cost-effectiveness analysis of magnetic resonance imaging-ultrasound fusion biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 25-25.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Trends and morbidity for minimally invasive versus open cytoreductive nephrectomy in the management of metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 632-632.	1.6	1
74	Preoperative anemia is associated with increased radical cystectomy complications. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 382.e7-382.e13.	1.6	1
75	Urinary Catheter Management for Nonurologists: A Resident Driven Educational Initiative. Urology Practice, 2017, 4, 85-90.	0.5	0
76	Editorial Comment. Journal of Urology, 2018, 199, 712-712.	0.4	0
77	The bladder cancer conundrum: how do we treat the right tumour with the right treatment, at the right time?. BJU International, 2019, 123, 748-749.	2.5	0
78	AUTHOR REPLY. Urology, 2020, 140, 121.	1.0	0
79	Impact of angiotensin inhibitors on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2021, 39, 432-432.	1.6	0
80	Cost-effectiveness analysis of pembrolizumab for BCG-unresponsive carcinoma in situ of the bladder.. Journal of Clinical Oncology, 2021, 39, 395-395.	1.6	0
81	Characterizing the costs of complications after cystectomy: Can we target the primary drivers?. Journal of Clinical Oncology, 2017, 35, 304-304.	1.6	0
82	Perioperative outcomes of aspirin use in radical prostatectomy.. Journal of Clinical Oncology, 2018, 36, 150-150.	1.6	0
83	Perioperative outcomes of aspirin use in partial nephrectomy.. Journal of Clinical Oncology, 2018, 36, 698-698.	1.6	0
84	Impact of sexual orientation on contemporary rates of prostate cancer screening.. Journal of Clinical Oncology, 2018, 36, 122-122.	1.6	0
85	Utilization and outcomes of chemoprophylaxis for the prevention of venous thromboembolism following radical cystectomy: A population-based study.. Journal of Clinical Oncology, 2018, 36, 491-491.	1.6	0
86	Incidence and predictors of mortality following major urologic cancer surgery.. Journal of Clinical Oncology, 2018, 36, 435-435.	1.6	0
87	Hospital variation in outcomes after surgery for prostate cancer.. Journal of Clinical Oncology, 2018, 36, 28-28.	1.6	0
88	Genomic profiling of variant urinary tract tumor histologies.. Journal of Clinical Oncology, 2019, 37, 450-450.	1.6	0
89	Resource utilization and cost efficacy analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2020, 38, e19390-e19390.	1.6	0
90	Dissecting outcomes of patients (pts) with ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration.. Journal of Clinical Oncology, 2020, 38, 5043-5043.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Impact of histology and toxicities on outcomes of patients with muscle invasive bladder cancer receiving neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2020, 38, 540-540.	1.6	0
92	Resource utilization analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2020, 38, 474-474.	1.6	0